Parallax Volatility Advisers’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Parallax Volatility Advisers’s Portfolio TTPH Stock Details TTPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-400	Closed	-$37K	–	3875
2016 Q1	$37K	Buy	+400	New	+$40K	﹤0.01%	2202

Other funds holding TTPH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Parallax Volatility Advisers's TTPH Position: Q3 2018 in Review

Parallax Volatility Advisers sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q3 2018, closing a stake of 80 shares — an estimated $6K sold.

Parallax Volatility Advisers first reported a position in TTPH in Q1 2016 and held it in 10 quarters. The position peaked at $62K in Q4 2017. 92 funds tracked by Wall St. Rank hold TTPH as of Q3 2018.

Parallax Volatility Advisers reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
Parallax Volatility Advisers sold 80 Tetraphase Pharmaceuticals, Inc. shares in Q3 2018, an estimated $6K.
Parallax Volatility Advisers first reported a position in Tetraphase Pharmaceuticals, Inc. in Q1 2016 and held it in 10 quarters.
Parallax Volatility Advisers's Tetraphase Pharmaceuticals, Inc. position peaked at $62K in Q4 2017.
92 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q3 2018.

Based on Parallax Volatility Advisers's 13F filing for Q3 2018, filed 14 Nov 2018.